They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Gardasil was 13% of Merck's sales in 2024, and roughly half of Gardasil sales tie to China. This increases reliance on Merck's oncology drug Keytruda (46% of sales), which could face biosimilar ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

Gardasil vaccine protects against cancer-causing ... Analysts had been projecting earnings of $9.13 per share on $67.07 billion in sales, according to FactSet. For the recently completed fourth ...